COMPREHENSIVE MEDICINAL CHEMISTRY II

Editors-in-Chief
Dr John B Taylor
Former Senior Vice-President for Drug Discovery, Rhône-Poulenc Rorer, Worldwide, UK
Professor David J Triggle
State University of New York, Buffalo, NY, USA

Volume 7
THERAPEUTIC AREAS II: CANCER, INFECTIOUS DISEASES, INFLAMMATION & IMMUNOLOGY AND DERMATOLOGY

Volume Editors
Dr Jacob J Plattner
Anacor Pharmaceuticals, Palo Alto, CA, USA

Dr Manoj C Desai
Gilead Sciences, Inc., Foster City, CA, USA
Contents

Contents of all Volumes xi
Preface xix
Preface to Volume 7 xxi
Editors-in-Chief xxiii
Editors of Volume 7 xxiv
Contributors to Volume 7 xxv

Anti Cancer

7.01 Cancer Biology 1
M-S MAIRA, M A PEARSON, D FABBRO, and C GARCÍA-ECHEVERRÍA, Novartis Institutes for BioMedical Research, Basel, Switzerland

7.02 Principles of Chemotherapy and Pharmacology 33
C K DONAWHO, A R SHOEMAKER, and J P PALMA, Abbott Laboratories, Abbott Park, IL, USA

7.03 Antimetabolites 55
M M MADER and J R HENRY, Lilly Research Laboratories, Indianapolis, IN, USA

7.04 Microtubule Targeting Agents 81
B R HEARN, S J SHAW, and D C MYLES, Kosan Biosciences, Hayward, CA, USA

7.05 Deoxyribonucleic Acid Topoisomerase Inhibitors 111
W A DENNY, University of Auckland, Auckland, New Zealand

7.06 Alkylating and Platinum Antitumor Compounds 129
R D HUBBARD and S FIDANZE, Abbott Laboratories, Abbott Park, IL, USA

7.07 Endocrine Modulating Agents 149
J A DODGE, T I RICHARDSON, and O B WALLACE, Lilly Research Laboratories, Indianapolis, IN, USA

7.08 Kinase Inhibitors for Cancer 183
A A MORTLOCK and A J BARKER, AstraZeneca, Macclesfield, UK

7.09 Recent Development in Novel Anticancer Therapies 221
H WEINMANN and E OTTOW, Schering AG, Berlin, Germany
Anti Viral

7.10 Viruses and Viral Diseases
E DE CLERCQ, Rega Institute for Medical Research, Leuven, Belgium

7.11 Deoxyribonucleic Acid Viruses: Antivirals for Herpesviruses and Hepatitis B Virus
E LITTLER, MEDIVIR UK Ltd, Little Chesterford, UK and X-X ZHOU, Medivir AB, Huddinge, Sweden

7.12 Ribonucleic Acid Viruses: Antivirals for Human Immunodeficiency Virus
T A LYLE, Merck Research Laboratories, West Point, PA, USA

7.13 Ribonucleic Acid Viruses: Antivirals for Influenza A and B, Hepatitis C Virus, and Respiratory Syncytial Virus
U SCHMITZ, L LOU, C ROBERTS, and R GRIFFITH, Genelabs Technologies, Inc., Redwood City, CA, USA

Anti Fungal

7.14 Fungi and Fungal Disease
P DORR, Pfizer Global Research and Development, Sandwich, UK

7.15 Major Antifungal Drugs
A S BELL, Pfizer Global Research and Development, Sandwich, UK

Anti Bacterials

7.16 Bacteriology, Major Pathogens, and Diseases
L S YOUNG, California Pacific Medical Center Research Institute, San Francisco, CA, USA

7.17 β-Lactam Antibiotics
C HUBSCHWERLEN, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

7.18 Macrolide Antibiotics
T KANEKO, T J DOUGHERTY, and T V MAGEE, Pfizer Global Research and Development, Groton, CT, USA

7.19 Quinolone Antibacterial Agents
A S WAGMAN, Novartis Institutes for BioMedical Research, Inc., Emeryville, CA, USA and M P WENTLAND, Rensselaer Polytechnic Institute, Troy, NY, USA

7.20 The Antibiotic and Nonantibiotic Tetracyclines
M L NELSON and M Y ISMAIL, Paratek Pharmaceuticals, Inc., Boston, MA, USA

7.21 Aminoglycosides Antibiotics
H A KIRST, Consultant, Indianapolis, IN, USA and N E ALLEN, Indiana University School of Medicine, Indianapolis, IN, USA

7.22 Anti-Gram Positive Agents of Natural Product Origins
V J LEE, Adesis, Inc., New Castle, DE, USA

7.23 Oxazolidinone Antibiotics
S J BRICKNER, Pfizer Inc., Groton, CT, USA

7.24 Antimycobacterium Agents
Z MA, A M GINSBERG, and M SPIGELMAN, Global Alliance for TB Drug Development, New York, NY, USA
7.25 Impact of Genomics-Emerging Targets for Antibacterial Therapy
J F BARRETT*, Merck Research Laboratories, Rahway, NJ, USA

Drugs for Parasitic Infections
7.26 Overview of Parasitic Infections
P J ROSENTHAL, University of California, San Francisco, CA, USA

7.27 Advances in the Discovery of New Antimalarials
K M MURALEEDHARAN and M A AVERY, University of Mississippi, University, MS, USA

7.28 Antiprotozoal Agents (African Trypanosomiasis, Chagas Disease, and Leishmaniasis)
P M WOSTER, Wayne State University, Detroit, MI, USA

I and I Diseases
7.29 Recent Advances in Inflammatory and Immunological Diseases: Focus on Arthritis Therapy
R MAGOLDA, Wyeth Research, Princeton, NJ, USA, and T KELLY, Boehringer-Ingelheim Inc., Ridgefield, CT, USA, and R NEWTON, Incyte Corporation, Wilmington, DE, USA, and J S SKOTNICKI, Wyeth Research, Pearl River, NY, USA, and J TRZASKOS, Bristol-Myers Squibb Corporation, Lawrenceville, NJ, USA

7.30 Asthma and Chronic Obstructive Pulmonary Disease
G P ROTH, Abbott Bioresearch Center, Worcester, MA, USA and D W GREEN, Amgen Inc., Cambridge, MA, USA

7.31 Treatment of Transplantation Rejection and Multiple Sclerosis
J S SKOTNICKI, Wyeth Research, Pearl River, NY, USA and D M HURYN, University of Pennsylvania, Philadelphia, PA, USA

Dermatology
7.32 Overview of Dermatological Diseases
H R JALIAN, S TAKAHASHI, and J KIM, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

7.33 Advances in the Discovery of Acne and Rosacea Treatments
S J BAKER, Anacor Pharmaceuticals, Palo Alto, CA, USA

7.34 New Treatments for Psoriasis and Atopic Dermatitis
M J ELICES, PharmaMar USA, Cambridge, MA, USA and T ARRHENIUS, Del Mar, CA, USA